Moderna lays out its case for boosters To view this email as a web page,
click here Regeneron's COVID-19 antibodies rake in $2.6B, reflecting their market dominance and blowing away estimates Cigna anticipates elevated claims costs for rest of 2021, execs say Moderna, citing variants and waning immunity, expects COVID-19 boosters to become a fact of life How COVID-19 impacted small businesses' health coverage Moderna abandons mid-stage mRNA cancer asset in favor of similar triple-attack candidate Featured Story | By Kevin Dunleavy Regeneron reported second quarter sales of $2.59 billion for its COVID-19 antibody treatment REGEN-COV, propelling the company to $5.14 billion in revenue. The performance blew away the Wall Street estimates. read more |
| |
|---|
|
Top Stories By Paige Minemyer Cigna posted $1.5 billion in profit in the second quarter of 2021, echoing its industry peers in seeing its earnings decline from Q2 2020. read more By Eric Sagonowsky For anyone thinking aggressive COVID-19 vaccine rollouts would bring a quick end to the pandemic, Moderna has a word of caution. While U.S. authorities aren’t yet ready to recommend vaccine boosters, the company believes that add-on shots will become a fact of life for some as the virus sticks around and continues to put up a fight. read more By Paige Minemyer Despite the challenges presented by COVID-19, the small group insurance market remained stable over the past year, according to a new study. read more By Annalee Armstrong Moderna has ditched a phase 2 asset in development for solid tumors, lymphoma and ovarian cancer to instead focus on a similar therapy that could put up a triple attack. The biotech, of COVID-19 vaccine fame, revealed in a second-quarter earnings release that the standalone OX40L candidate mRNA-2416 will be shelved in favor of mRNA-2752. read more |
|
